MQ710

AXP000192.1 · Viral vector gene therapy

Platform
MVA (E5R-deleted)
Originator
Memorial Sloan Kettering Cancer Center
Sponsor
Memorial Sloan Kettering Cancer Center

Names

NameTypeSource
MQ710preferred name, codecurator, ncit
MVAdeltaE5R-Flt3L-OX40Lsynonymncit

Virus

Role
In vivo gene transfer
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA (E5R-deleted)
Replication
non replicating
Modifications
E5R deleted; Flt3L and OX40L cassettes inserted
Transgenes
FLT3LG, TNFSF4
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C199613

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05859074A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerRecruitingPhase 12023-05-042028-05-0456Adnexal Carcinoma; Advanced Cancer; Angiosarcoma; BCC; BCC - Basal Cell Carcinoma; Basal Cell Carcinoma; Cutaneous Neoplasm; Cutaneous Squamous Cell Carcinoma; Extramammary Paget Disease; HNSCC; Head and Neck Squamous Cell Carcinoma; Kaposi Sarcoma; Melanoma; Merkel Cell Carcinoma; Metastatic Cancer; Refractory Cancer; SCC - Squamous Cell Carcinoma; Sebaceous Carcinoma; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Notes

Non-replicating MVA with an E5R deletion expressing human Flt3L (FLT3LG) and OX40L (TNFSF4), injected intratumorally alone or with pembrolizumab; phase 1 NCT05859074. Recorded as in_vivo_gene_transfer rather than vaccine_vector because it delivers immune-stimulatory ligands, not a tumour antigen; it is not oncolytic (MVA does not replicate in human cells).

How to cite

MQ710 (AXP000192.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000192.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.